ArticleInflammopharmacology2026
Chemical profile and anti-inflammatory activity of the hydroethanolic extract of Cochlospermum regium (Schrank) Pilg. xylopodium.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimCochlospermum regium is widely distributed in the Brazilian Cerrado, where its xylopodium is traditionally used to treat inflammatory disorders. This study investigated the anti-inflammatory effects of the hydroethanolic extract of C. regium xylopodium (HECr) using in vivo and in vitro models and characterized its phytochemical profile. EXPERIMENTAL PROCEDURES: A 70% hydroethanolic extract was prepared from the xylopodium and subjected to phytochemical analysis. In vivo assays were conducted in male Swiss mice treated with HECr (25, 100, or 400 mg/kg) and evaluated in acetic acid-induced vascular permeability and lipopolysaccharide (LPS)-induced peritonitis models. Total and differential leukocyte counts, and cytokine levels were determined in peritoneal fluid. In vitro, RAW 264.7 macrophages were used to assess cytotoxicity, nitric oxide (NO) production, and inflammatory cytokine release after LPS stimulation.
resultsPhytochemical analysis identified myricetin-3-O-β-D-galactopyranoside, quinic acid, and quercetin-3-O-rhamnoside as major constituents. HECr significantly reduced Evans blue extravasation in the vascular permeability assay. In LPS-induced peritonitis, HECr decreased total leukocyte and neutrophil migration, reduced TNF-α and IL-1β levels, and increased IL-10 concentrations compared with vehicle-treated controls. In LPS-stimulated macrophages, HECr (1–20 µg/mL) reduced IL-1β and NO production, decreased TNF-α at lower concentrations, increased IL-13 levels, and showed no cytotoxicity.
conclusionsHECr exhibits significant anti-inflammatory activity, likely mediated by modulation of vascular permeability, leukocyte recruitment, cytokines, and NO, supporting its traditional use and potential therapeutic application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.